Canaccord Genuity’s $20 target on ANGO

ANGO Angiodynamics Inc

$11.5 → $20 (+74%) by Oct 2027

Buy · reiterates · said Oct 9, 2026 · 12-month default horizon

Open: judged on the close on Oct 9, 2027

The article this target came from

Canaccord reiterates AngioDynamics stock rating on growth platforms

Investing.com · Oct 9, 2026

Canaccord Genuity reiterated a Buy rating and $20.00 price target on AngioDynamics Inc.

Canaccord Genuity’s track record → Angiodynamics Inc →

A fact about what Canaccord Genuity published, as reported by Investing.com, not a recommendation from Dalsna Finance; Canaccord Genuity is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.